Evidence map›Paper›PMID 35881212›Full record

ArticleChinese journal of integrative medicine2023

Meranzin Hydrate Improves Depression-Like Behaviors and Hypomotility via Ghrelin and Neurocircuitry.

Ya-Lin Liu, Jian-Jun Xu, Lin-Ran Han, Xiang-Fei Liu, Mu-Hai Lin, Yun Wang, Zhe Xiao, Yun-Ke Huang, Ping Ren, Xi Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Chinese journal of integrative medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ya-Lin LiuInstitute of Traditional Chinese Medicine-Related Comorbid Depression, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Jian-Jun XuInstitute of Traditional Chinese Medicine-Related Comorbid Depression, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Lin-Ran HanDepartment of Outpatient, Xuzhou Central Hospital, Xuzhou, Shangdong Province, 221000, China.
Xiang-Fei LiuInstitute of Traditional Chinese Medicine-Related Comorbid Depression, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Mu-Hai LinInstitute of Traditional Chinese Medicine-Related Comorbid Depression, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Yun WangInstitute of Traditional Chinese Medicine-Related Comorbid Depression, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Zhe XiaoInstitute of Traditional Chinese Medicine-Related Comorbid Depression, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Yun-Ke HuangDepartment of Obstetrics and Gynecology, Women's Hospital School of Medicine, Zhejiang University, Hangzhou, 310006, China.
Ping RenDepartment of Geriatrics, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Xi HuangInstitute of Traditional Chinese Medicine-Related Comorbid Depression, Nanjing University of Chinese Medicine, Nanjing, 210023, China. tcmhuangx59@163.com.
Nanjing University of Chinese Medicine · CNWomen's Hospital, School of Medicine, Zhejiang University · CNXuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate whether meranzin hydrate (MH) can alleviate depression-like behavior and hypomotility similar to Chaihu Shugan Powder (CSP), and further explore the potential common mechanisms.

methodsTotally 120 Spraque-Dawley rats were randomly divided into 5-8 groups including sham, vehicle, fluoxetine (20 mg/kg), mosapride (10 mg/kg), CSP (30 g/kg), MH (9.18 mg/kg), [D-Lys3]-GHRP-6 (Dlys, 0.5 mg/kg), and MH+Dlys groups by a random number table, 8 rats in each group. And 32 mice were randomly divided into wild-type, MH (18 mg/kg), growth hormone secretagogue receptor-knockout (GHSR-KO), and GHSR+MH groups, 8 mice in each group. The forced swimming test (FST), open field test (OFT), tail suspension test (TST), gastric emptying (GE) test, and intestinal transit (IT) test were used to assess antidepressant and prokinetic (AP) effects after drug single administration for 30 min with absorbable identification in rats and mice, respectively. The protein expression levels of brain-derived neurotrophic factor (BDNF) and phosphorylated mammalian target of rapamycin (p-mTOR) in the hippocampus of rats were evaluated by Western blot. The differences in functional brain changes were determined via 7.0 T functional magnetic resonance imaging-blood oxygen level-dependent (fMRI-BOLD).

resultsMH treatment improved depression-like behavior (FST, OFT) and hypomotility (GE, IT) in the acute forced swimming (FS) rats (all P<0.05), and the effects are similar to the parent formula CSP. The ghrelin antagonist [D-Lys3]-GHRP-6 inhibited the effect of MH on FST and GE (P<0.05). Similarly, MH treatment also alleviated depression-like behavior (FST, TST) in the wild-type mice, however, no effects were found in the GHSR KO mice. Additionally, administration of MH significantly stimulated BDNF and p-mTOR protein expressions in the hippocampus (both P<0.01), which were also prevented by [D-Lys3]-GHRP-6 (P<0.01). Besides, 3 main BOLD foci following acute FS rats implicated activity in hippocampus-thalamus-basal ganglia (HTB) circuits. The [D-Lys3]-GHRP-6 synchronously inhibited BOLD HTB foci. As expected, prokinetic mosapride only had effects on the thalamus and basal ganglia, but not on the hippocampus. Within the HTB, the hippocampus is implicated in depression and FD.

conclusionsMH accounts for part of AP effects of parent formula CSP in acute FS rats, mainly via ghrelin-related shared regulation coupled to BOLD signals in brain areas. This novel functionally connection of HTB following acute stress, treatment, and regulation highlights anti-depression unified theory.

Indexed as

Brain-Derived Neurotrophic FactorGhrelinAnimalsAntidepressive AgentsBenzamidesCoumarinsHippocampusMammalsMiceMorpholinesRatsSalicylatesStress, Psychological4-trifluoromethylsalicylic acidAntidepressive AgentsBenzamidesBrain-Derived Neurotrophic FactorCoumarinsGhrelinmeranzin hydrateMorpholinesmosaprideSalicylatesblood oxygen level-dependentChinese medicinecomorbiditydepressionGan (Liver) governing free flow of qighrelinhypomotility

Identifiers

PMID35881212
OpenAlexW4287921609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.